
Dr. John Cush RheumNow
1 year 6 months ago
Psoriatic Arthritis Topic Panel
https://t.co/I3puVr5HWa https://t.co/sCzjnnDG1G


Dr. John Cush RheumNow
1 year 6 months ago
Day 2 Report - ACR Plenaries: Changing the Practice of Rheumatology
The top ACR2023 Plenary abstracts Dr. Dao ( @kdao2011) found impactful for her practice were...
https://t.co/aXut7l7b79 https://t.co/ATO5r5OzGK

Chronic low back pain is a common complaint that brings patients to the doctor’s attention. Although the majority of low back pain is mechanical in nature, an important minority is inflammatory in nature. Therefore, prompt referral to a rheumatologist is warranted particularly in the presence of other features suggestive of axial spondyloarthritis (axSpA).
Drs. Jack Cush and Arthur Kavanaugh discuss highlights and key takeaways from ACR 23.

Dr. John Cush RheumNow
1 year 6 months ago
ACR23 – Day 3 Report
F2F learning amidst miles of research and many young talented aside wizened establish presenters is such a welcome return to ACR, the way it should be.
https://t.co/TwmwfEQZdp https://t.co/Yo27c7ig8N


Dr. John Cush RheumNow
1 year 6 months ago
Watch: Lupus Nephritis Therapy Paradigm Shift
Dr. Yuz Yusof reporting on abstract 0782 at the 2023 ACR Convergence meeting in San Diego, CA.
https://t.co/poIVX74EnO https://t.co/tWlRlwTfH0


Dr. John Cush RheumNow
1 year 6 months ago
IV Secukinumab for AxSpa
The FDA recently announced approval for intravenous secukinumab (Cosentyx) for adults with psoriatic arthritis, ankylosing spondylitis, and non-radiographic spondylitis.
https://t.co/eDAWevPLkE https://t.co/AlWYGAQP5T


Dr. John Cush RheumNow
1 year 6 months ago
Secukinumab vs. Adalimumab Biosimilar on Radiographic Progression in AxSpA
Dr. Robert Chao (Tysons, VA) discusses Abstract 0522 presented at the 2023 ACR Convergence meeting in San Diego, CA.
https://t.co/UmcbplfGhB https://t.co/R5Lr6Q0qHI


Dr. John Cush RheumNow
1 year 6 months ago
How early is early in psoriatic arthritis?
Is there a window of opportunity for treatment in PsA to ensure optimal outcomes?
https://t.co/SHA8Gdm1GD https://t.co/GbFfeB2Euw


Dr. John Cush RheumNow
1 year 6 months ago
Cancer and TNF inhibitors
Cancer risk minimisation is a high priority for people with rheumatic diseases, as it is for the general population. Tumor necrosis factor inhibitors (TNFi) have a long history of association with cancer risk discussions
https://t.co/MzksmSEUjf https://t.co/dxCIHxL1gc
